研究单位：[1]Shiyao Group Ouyi Pharmaceutical Co., Ltd.[2]CSPC ZhongQi Pharmaceutical Technology Co., Ltd.[3]Anhui Cancer Hospital,Hefei,Anhui,China[4]Maanshan People''s Hospital,Maanshan,Anhui,China[5]Hainan General Hospital,Haikou,Hainan,China[6]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[7]Tumor Hospital of Harbin Medical University,Harbin,Heilongjiang,China[8]Henan Cancer Hospital,Zhengzhou,Henan,China[9]Inner Mongolia Autonomous Region Cancer Hospital,Hohhot,Inner Mongolia Autonomous Region,China[10]Liaoning Cancer Hospital,Shenyang,Liaoning,China[11]Zhongshan Hospital,Shanghai,Shanghai,China[12]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China[13]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shanxi,China[14]The Second Affiliated Hospital of Xi''an Jiaotong University (Xibei Hospital),Xi''an,Shanxi,China[15]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[16]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China
研究目的：
This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.
